Pulmonx (NASDAQ:LUNG) Announces Earnings Results

Pulmonx (NASDAQ:LUNG) announced its quarterly earnings results on Wednesday. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04, FiscalAI reports. Pulmonx had a negative net margin of 60.09% and a negative return on equity of 92.94%. The firm had revenue of $22.76 million for the quarter, compared to analysts’ expectations of $22.39 million.

Here are the key takeaways from Pulmonx’s conference call:

• Second-quarter revenue was $22.8 million, down 5% year over year. U.S. revenue declined 4% but increased 7% sequentially, while the international decline was attributed to the suspension of China shipments; 12 new U.S. treating centers were added.
• Management reiterated its 2026 revenue guidance of $90 million to $92 million and expects to return to year-over-year growth later this year, potentially exiting 2026 at or near double-digit growth as new sales representatives ramp.
• Cost reductions produced meaningful operating leverage: net loss fell 34% to $10.1 million and adjusted EBITDA loss improved nearly 40% to $5.1 million. Full-year operating expenses are now expected at $109 million to $111 million, with cash burn projected at approximately $23 million.
• Pulmonx renewed its Chinese registration certificate in June and expects to resume distributor shipments in early 2027; excluding China, international revenue grew 9% on a constant-currency basis. Second-quarter gross margin rose to 78%, and full-year guidance was raised to approximately 76%.
• Enrollment in the pivotal CONVERT II trial for AeriSeal is progressing toward completion in 2027. Management views AeriSeal as a potential tool to expand the global addressable market for Zephyr valves by roughly 20%, with earlier commercial availability possible in certain European markets after local enrollment is complete.

Pulmonx Stock Performance

Pulmonx stock remained flat at $1.25 during midday trading on Wednesday. The company had a trading volume of 210,647 shares, compared to its average volume of 458,741. The business’s 50 day moving average is $1.42 and its two-hundred day moving average is $1.47. Pulmonx has a 1 year low of $1.13 and a 1 year high of $3.39. The company has a market capitalization of $52.80 million, a PE ratio of -0.96 and a beta of 0.30. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.04 and a current ratio of 4.91.

Analyst Ratings Changes

Several analysts have issued reports on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Pulmonx in a research report on Thursday, April 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research report on Monday, July 13th. Finally, Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pulmonx currently has a consensus rating of “Hold” and a consensus price target of $5.58.

Institutional Trading of Pulmonx

A number of institutional investors and hedge funds have recently modified their holdings of the business. Cerity Partners LLC bought a new position in shares of Pulmonx during the fourth quarter valued at approximately $27,000. Opal Capital LLC acquired a new position in shares of Pulmonx during the fourth quarter valued at $29,000. Jain Global LLC bought a new position in shares of Pulmonx during the third quarter worth about $30,000. Lazard Asset Management LLC bought a new position in shares of Pulmonx during the fourth quarter worth about $31,000. Finally, Two Sigma Investments LP increased its holdings in shares of Pulmonx by 50.3% in the 3rd quarter. Two Sigma Investments LP now owns 46,456 shares of the company’s stock worth $75,000 after acquiring an additional 15,557 shares during the period. 91.04% of the stock is owned by institutional investors and hedge funds.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.